Kornimate/medical-research-clean huggingface dataset:
efficacy of antimicrobial coating suture coated vicryl plus compared with vicryl in reduced surgical site infection of dental implant surgeries: a uni-blind randomized clinical trial study

Conditions: Infection, Surgical Site

Summary: patients randomly aligned in 2 groups.vicryl plus sutures were used in group 1 for closing subperiostal flaps after dental implant surgeries and vicryl sutures were used in group 2.

patients were divided randomly based on computer randomization list in two groups: in group1, vicryl plus 4-0 (vicryl plus ethicon,johnson \& johnson company, sommerville, nj) suture was used to close surgical site and vicryl 4-0 (vicryl ethicon,johnson \& johnson company, sommerville, nj) in group ii. all dental implants were placed through creating subperiosteal flaps. in each group, fresh socket placed dental implants were documented. patients were visited in 1, 2, 3 and 4 weeks after dental implant surgeries. postoperative infection was defined as local erythematous change in the sutured wound with purulent discharge or localized abscess formation on surgical site. if wound dehiscence occurred, it was documented. patients were blind about what suture was used.

Eligibility criteria:
inclusion criteria: * need 3 dental implants at the posterior of the mandible exclusion criteria: * diabetic patients * smoker * poor oral hygiene

Keywords: sutures surgical wound infection polyglactin 910
haloperidol for the treatment of nausea and vomiting in the ed

Conditions: Vomiting; Nausea; Abdominal Pain; Cannabis Use

Summary: single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ed) with a chief complaint of nausea or vomiting. a total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from february 2021 - february 2022. patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. follow-up will be performed by telephone at 24 hours.


Eligibility criteria:
inclusion criteria: * presenting to the emergency department with chief complaint of nausea or vomiting exclusion criteria: * abnormal blood pressure (\>200/100mmhg or \<90/40mmhg), * fever (\>100.4f), * acute trauma, * qt \> 450ms on cardiac monitor, * altered mental status (gcs \< 15), * chest pain, * known allergy to haloperidol or ondansetron, * parkinson's disease, * pregnancy or lactation, * use of any antiemetic in the previous 8 hours, * nausea and vomiting associated with vertigo, * prisoners or any wards of the state.
zinc to treat tinnitus in the elderly

Conditions: Tinnitus

Summary: there is widespread belief and some evidence to indicate that zinc can successfully treat tinnitus. zinc deficiency is more likely to occur in the elderly . the primary objective of this study is to establish the effectiveness of zinc for the treatment of tinnitus in individuals 60 years of age and older. subjects will be randomly assigned to either receive zinc daily or a placebo. after 4 months and a 1-month wash-out, the subjects will be crossed over to the other group.

there is widespread belief and some evidence to indicate that zinc can successfully treat tinnitus. zinc deficiency is more likely to occur in the elderly . the primary objective of this study is to establish the effectiveness of zinc for the treatment of tinnitus in individuals 60 years of age and older. subjects will be randomly assigned to either receive zinc daily or a placebo. after 4 months and a 1-month wash-out, the subjects will be crossed over to the other group. 116 patients were tested. tinnitus loudness and the tinnitus handicap questionnaire are the outcome measures.

Eligibility criteria:
inclusion criteria: * 60 years of age or older * tinnitus for 6 months or more * normal copper levels * be generally healthy exclusion criteria: * have a treatable otological disorder * involved in litigation * have or are suspected of having a serious psychiatric problem * involved in other treatments for tinnitus * are taking drugs which might interact with zinc and result in tinnitus * have copper deficiency * have zinc levels above normal * are cognitively impaired.

Keywords: tinnitus, zinc
treatment outcome in elderly patients

Conditions: AML; Elderly Patients

Summary: a multicenter randomized trial evaluating the possible benefit of androgens during post remission therapy in an attempt to improve the outcome of aml in older patients.all patients received the icl regimen as induction and were randomized to receive, after achieving cr or pr, a maintenance therapy including or not androgens. patients randomized with androgens additionally received 10 to 20 mg according to body weigh of norethandrolone daily for up to 2 years

* induction therapy: * idarubicin, 8mg/m2 d1-5; cytarabine, 100mg/m2 d1-7 and lomustine, 200mg/m d1 * if cr or pr: randomisation = maintenance therapy including or not androgens * maintenance therapy : * 6 courses of reinduction with idarubicin (8mg/m2 d1) and cytarabine (100mg/m2d1-5, subcutaneously) every 3 months, and, between these courses, a continuous regimen of methotrexate and 6-mercaptopurine. * patients randomized with androgens additionally received 10 to 20 mg according to body weigh of norethandrolone daily for up to 2 years

Eligibility criteria:
inclusion criteria: * patients aged 60 years or more * "de novo" aml according to fab criteria * aml with 20% or more myeloid marrow blasts * signed and dated informed consent * oms score \< 3 * life expectancy \> 1 month exclusion criteria: * patients aged \< 60 years * or aml m3 * or not classificated according to fab criteria * or extramedular localisation of aml * oms score ≥ 3 * clinical abnormal cardiac fonction or with left ejection fraction \< 40 % * abnormal renal function with creatinine clearance \< 50/ml/mn/m² * abnormal hepatic function * previous cerebral stroke * previous malignancy : prostate, breast cancer (males) * psa dosage \> 4 * any coexisting medical or psychological condition that would pleclude participation in the required study procedures

Keywords: aml elderly patients treatment outcome
living after a rare cancer of the ovary: chronic fatigue, quality of life and late effects of chemotherapy

Conditions: Germ Cell Tumor; Sex Cord Stromal Tumor; Malignant Non-epithelial Ovarian Tumors

Summary: while they are documented in patients in remission of testicular cancer, the sequelae of chemotherapy and the impact of the disease and its treatments on the living conditions and qol of women in remission of rare ovarian cancer remain poorly explored. the coordinator therefore propose a national 2-step case-control study to evaluate 1) chronic fatigue and qol and 2) chemotherapy-related sequelae in adult patients in remission of surgery-treated tgmo or tscs (conservative or not) supplemented with chemotherapy


Eligibility criteria:
inclusion criteria: * age\> 18 years; * patient with an ovarian malignant germ cell tumor (tgmo) or a stroma tumor and / or sex cords (tscs) treated optimally; * patient who has had surgery and chemotherapy (interest group) or only a surgery (control group); * patient in remission more than 2 years after the end of the initial treatment; * relapse authorized if remission more than 2 years after the end of the treatment; * patient with no other cancers (with the exception of basal cell skin carcinomas, in situ cancers of the breast and cervix); * patient having signed his consent to participate exclusion criteria: * pregnant or breastfeeding woman; * psychiatric pathology that may disrupt the course of the study or prevent the interpretation of results; * person deprived of liberty; * major subject to a legal protection measure or unable to express his consent.
neoadjuvant durvalumab alone or in combination with novel agents in resectable non-small cell lung cancer

Conditions: Resectable; Early-stage; NSCLC

Summary: study d9108c00002 (neocoast) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (stage i \[\>2cm\] to iiia) non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: 1. cytologically and/or histologically-documented nsclc 1. stage i (\> 2 cm) to iiia (for participants with n2 disease, only those with 1 single nodal station ≤ 3 cm are eligible) nsclc according to the 8th edition of american joint committee on cancer staging classification 2. amenable to complete surgical resection 3. have not received any other therapy for this condition 2. predicted forced expiratory volume in one second (fev1) ≥ 50% 3. predicted diffusing capacity of the lungs for carbon monoxide (dlco) ≥ 50% 4. ecog 0 or 1 5. adequate organ function exclusion criteria: 1. participants with small-cell lung cancer or mixed small-cell lung cancer 2. participants who require or may require pneumonectomy 3. prior treatment with programmed cell death ligand-1 (pd-l1), pd-l1, or cytotoxic t-lymphocyte antigen 4 (ctla-4) inhibitors 4. current or prior use of immunosuppressive medication within 14 days before the first dose of study drug. 5. active or prior documented autoimmune or inflammatory disorders. the following are exceptions to this criterion: 1. participants with vitiligo or alopecia 2. participants with hypothyroidism on hormone replacement 3. any chronic skin condition that does not require systemic therapy 4. participants without active disease in the last 5 years may be included but only after consultation with the study physician 5. participants with celiac disease controlled by diet alone 6. pregnant or breast-feeding female 7. major surgical procedure within prior 30 days 8. history of active primary immunodeficiency 9. active infection including tuberculosis, hepatitis b, hepatitis c, or hiv 10. qtc interval (qtc) ≥ 470 ms 11. uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring aes or compromise the ability of the participant to give written informed consent 12. receipt of live attenuated vaccination within 30 days prior to study entry 13. history of another primary malignancy except for: 1. curative-treated malignancy with no known active disease \> 2 years before enrollment on the study 2. curative-treated non-melanoma skin cancer and/or carcinoma in-situ

Keywords: neoadjuvant non-small cell lung cancer cancer lung resectable early-stage stage i stage ii stage iiia durvalumab
mental health first aid for college students

Conditions: Depression; Anxiety; Suicidal Ideation; Eating Disorders

Summary: most college students with mental disorders do not receive treatment, and over 80% of those who die by suicide have never made contact with campus mental health services. knowledge, stigma, and other health beliefs represent significant barriers to help-seeking for many of these students. however, there have been no large-scale intervention studies for reducing these barriers to mental health treatment on college campuses. this project will fill this gap by determining whether a community mental health education program, mental health first aid (mhfa), is an effective method to increase number of students who seek mental health services on college campuses. mhfa is an international, 12-hour training program that has been shown to increase knowledge of mental illnesses and their treatments, decrease stigma, and increase helping behaviors in community members. however, it has not been tested in a college setting in the united states. to determine the effectiveness of mhfa in us colleges, the proposed project will involve a randomized control trial of the mhfa training program on 32 campuses representing a range of higher education institutions, from community colleges in rural areas to research universities in large, urban areas. the mhfa training program will be administered to peer supports such as residential advisors. administrative data from campus mental health services and pre- and post-intervention surveys will be used to collect outcome data on service utilization, knowledge, attitudes, and other measures. data analyses will focus on identifying changes in students' behaviors, knowledge, and attitudes toward mental illnesses that can be attributed to the mhfa training. in addition to testing a novel and timely mental health intervention for college students, this project will result in improved data collection measures for college populations, and will lay the foundation for stronger connections and future collaborations between diverse campus communities. if the mhfa program is successful in reducing stigma and increasing general on-campus awareness and early treatment of emerging mental health problems, then it may provide a cost-effective means for enabling more students to seek early treatments for developing mental health problems.


Eligibility criteria:
inclusion criteria: * student enrolled in a participating campus as a full-time, residential undergraduate during the 2009-2010 or 2010-2011 academic years. student must have been living in a participating residence hall. exclusion criteria: * students under 18 years of age.
tiotropium induced bronchodilation in lung ct scored emphysema

Conditions: COPD; Emphysema

Summary: to evaluate if tiotropium (spiriva)induced bronchodilation of inspiratory capacity in patients with moderate to severe copd subjected to metronome paced hyperventilation induced dynamic hyperinflation is dependent upon the extent of underlying emphysema as determined by high resolution-thin section ct lung.

we will analyze post hoc, data that was previously published: gelb af et al.chest 2006;131:690-695. we have shown that tiotropium increases resting inspiratory capacity thereby providing lung volume protection against metronome paced hyperventilation induced dynamic hyperinflation. end point will be to correlate increase in tiotropium induced fev 1(l) and inspiratory capacity with extent of underlying emphysema as scored by lung ct ( gelb af et al:chest 1996; 109: 353-359)in 29 patients with copd. we will also correlate the decrease in inspiratory capacity following metronome paced hyperventilation induced dynamic hyperinflation with extent of lung ct scored emphysema.

Eligibility criteria:
inclusion criteria * moderate to severe copd exclusion criteria * unable to tolerate tiotropium * unable to perform metronome paced hyperventilation induced dynamic hyperinflation

Keywords: copd emphysema tiotropium lung function dynamic hyperinflation
swiss atrial fibrillation cohort study

Conditions: Atrial Fibrillation

Summary: swiss-af is a prospective observational, multicentric cohort study in switzerland. overall, 2600 patients with documented atrial fibrillation aged \>65 years will be included and followed on a yearly basis. yearly clinical examinations include a detailed questionnaire on personal characteristics, a resting electrocardiogram, neurocognitive function tests and questionnaires on disability and quality of life. blood sampling and brain magnetic resonance imaging are scheduled at baseline and after 2 years of follow-up. the main study aims of this long term prospective study are to increase our knowledge on structural brain damage and its changes over time in patients with atrial fibrillation, to gain additional insights on the incidence and underlying mechanisms of cognitive decline in patients with atrial fibrillation and to evaluate the interrelationships of structural and functional brain damage in this population.


Eligibility criteria:
inclusion criteria: * atrial fibrillation documented within the last 24 months * age \>=45 years exclusion criteria: * acute illness * inability to provide informed consent * only short episodes of reversible forms of atrial fibrillation

Keywords: atrial fibrillation dementia cognitive dysfunction stroke magnetic resonance imaging
issues and challenges in cancer patients on active treatment during the covid-19 pandemic

Conditions: Oncology Patients

Summary: in view of increasing cases of sars-cov-2 leading to the covid-19 pandemic in india,there has been unprecedented restrictions on travel, work and other aspects of daily life. our study has been designed to collect data of cancer patients to analyze their issues and challenges during covid-19 pandemic.

protocol no: onco_covid-19 version no:1.0 objectives: firstly the patients recently diagnosed with cancer will be selected for enrollment who are on active treatment during lockdown based on the date of their registration in the hospital. this is followed by a telephonic interview with patients or their attendant to carry out a prospective, cross-sectional, observational study in order to address the issues and challenges faced by them during lockdown. collection of data will be done through telephonic communication. participation in this study will be entirely voluntary. telephonic verbal consent will be taken from the patients or their attendants before collection of their response on the study questionnaire and then will be asked questions accordingly based on the questionnaire which is available in english and hindi both. data and general information regarding participants will only be collected in questionnaire. no personal data of the participants will be taken which will also be conveyed to the participant or attendant during telephonic verbal consent.

Eligibility criteria:
inclusion criteria: * registered with the max institute of cancer care between nov 1st 2019 to jan 31st 2020 * were scheduled to receive one or more modalities of treatment (chemotherapy, surgery, radiation therapy, immunotherapy) during the period feb 1st 2020 to april 30th 2020 exclusion criteria: -
virtual reality exposure therapy in the intensive treatment of social anxiety disorder

Conditions: Phobia

Summary: to explore the efficacy of drugs combined with virtual reality exposure therapy in the treatment of phobias compared with single drug treatment.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for phobias in dsm-iv. * age from 18 to 45 years old. * graduated from junior high school or above. * no serious physical disease, no serious visual impairment, and no family history of mental illness. exclusion criteria: * exclude other psychiatric diagnosis and treatment history.

Keywords: phobia vr
carbohydrate counting and bolus calculator mobile application improves time in range in adults with type 1 diabetes

Conditions: Diabetes Mellitus, Type I

Summary: introduction: accurate insulin bolusing requires advanced knowledge of carbohydrate counting and correction doses, which can be supported by mobile technology. objective: to evaluate the effectiveness and safety of a mobile application for carbohydrate counting and bolus calculation (choc-bc) in adults with type 1 diabetes mellitus (t1dm). methods: this is a 12-week randomized controlled trial conducted at king fahad medical city. adults with t1dm using multiple daily insulin injections and libre flash glucose monitoring systems are randomly assigned to either the choc-bc intervention group or a control group receiving conventional treatment. the primary endpoint is the time in range (tir; 70-180 mg/dl).

this is a single-center, randomized, controlled trial evaluating the effectiveness of a mobile application, choc-bc, designed to assist adults with type 1 diabetes mellitus (t1dm) in carbohydrate counting and insulin bolus calculation. the study is conducted at king fahad medical city over a 12-week period. participants are randomized into two groups: the intervention group uses the choc-bc mobile app, while the control group continues with standard diabetes management practices. participants are required to use flash glucose monitoring systems and multiple daily insulin injections. the primary outcome is the percentage of time that glucose levels remain within the target range (70-180 mg/dl), assessed using continuous glucose data. secondary outcomes include time spent in hypoglycemia and hyperglycemia, changes in body weight, and user engagement with the application. the study seeks to determine whether digital support tools can improve glycemic outcomes and simplify self-management among adults with t1dm.

Eligibility criteria:
inclusion criteria: male or female participants aged 18-60 years clinical diagnosis of type 1 diabetes mellitus (t1dm) for at least one year hba1c \>6.5% (48 mmol/mol) using multiple daily insulin injections as the method of t1dm treatment basic knowledge of carbohydrate counting (choc) regular use of a smartphone operating on ios 13 or higher or android 11 active users of the libre 2 flash glucose monitoring system sensor capture rate greater than 30% exclusion criteria: limited literacy use of an insulin pump pregnant or breastfeeding diagnosed with ischemic heart disease presence of multiple comorbidities where low glucose levels may pose a risk unwillingness or inability to comply with the study protocol following a very low-carbohydrate diet (\<10% of daily intake from carbohydrates)
comparison of transtibial and transfemoral amputees' posture parameters

Conditions: Amputation; Traumatic, Limb; Postural; Defect

Summary: with the onset of prosthesis use following lower extremity amputations, body shows biomechanical changes according to the amputation level and consequently develops adaptation mechanisms both on the healthy and ampute side. the aim of this study is to determine the static postural adaptations that appear at different amputation levels.


Eligibility criteria:
inclusion criteria: * being between the ages of 18-65 * having had an amputation at least 6 months ago * have had transfemoral amputation or transtibial amputation * to be able to perform ambulation independently exclusion criteria: * mental inability to understand commands * have a neurological, orthopedic and systemic problem that will negatively affect posture or gait.

Keywords: amputation, postural adaptations, transtibial, transfemoral
dose-ranging study of nemolizumab in atopic dermatitis

Conditions: Atopic Dermatitis

Summary: assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (ad) subjects with severe pruritus receiving tcs, who were not adequately controlled with topical treatments.

the aim of the study is to assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (ad) subjects with severe pruritus receiving topical corticosteroids, who were not adequately controlled with topical treatments.

Eligibility criteria:
inclusion criteria: * male or female subjects ≥ 18 years (or legal age when higher) * chronic ad, that has been present for at least 2 years before the visit * eczema area and severity index (easi) score ≥12 * investigator global assessment (iga) score ≥ 3 * ad involvement ≥ 10% of body surface area (bsa) * severe pruritus on at least 3 of the last 7 days before the visit * documented recent history (within 6 months before the visit) of inadequate response to topical medications * female subjects must fulfill one of the criteria below: * female subjects of non-childbearing potential * female subjects of childbearing potential who agree to a true abstinence or to use an effective or highly effective method of contraception throughout the clinical trial and for 120 days after the last study drug administration exclusion criteria: * body weight \< 45 kg * subjects with a medical history of asthma requiring hospitalization in the last 12 months before screening visit and/or whose asthma has not been well-controlled during the last 3 months before the screening visit and/or peak expiratory flow (pef) \<80% of the predicted value * cutaneous bacterial or viral infection within 1 week before the screening visit or during the run-in period * infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 1 week before the screening visit or during the run-in period * history of intolerance to low or mid potency tcs or for whom tcs is not advisable